Regen® Innovative Preparations focus on Autologous Cell-Based Preparations, including the rapid preparation of Platelet-Rich Plasma (PRP).
RegenKit® Medical Devices were introduced to the U.S.A. in 2010, and we began U.S. Manufacturing in November 2021. Along with these platforms, and Regen® preparation methods, came the availability of Regen® A-PRP® and Autologous Thrombin Serum (Regen® ATS).
Regen® A-PRP® represents a class of preparations which utilize unique cellular selectivity models to produce RegenPlasma® and RegenCell®.
Learn more about Regen® A-PRP®
Regen® innovative preparation methods have grown into the RegenPRP™ methodology for autologous cellular therapies, though standardization and education.
RegenLab® develops, manufactures, and distributes easy-to-use medical devices, with a focus on patient safety, product quality, biological efficacy, and preparation efficiency.
Our patient-centered technology has led to over two-million treatments provided worldwide, using RegenLab® Medical Device Kits.
In 2021, our U.S. Production facility opened with the purpose of bringing our award-winning products closer to the U.S. market, for purposes of increased patient accessibility.
RegenLab®, Regen®, RegenKit®, THT®, RegenPlasma®, RegenCell®, RegenBMC®, VetPRP®, CellularMatrix®, A-PRP® & BioBridge® are U.S. registered trademarks of RegenLab USA and/or Regen Lab SA.
RegenWound™, RegenPRP™, RegenMatrix™, RegenARP™, ArthroVisc™, SkinVisc™, Generation Regeneration™ & RegenVet™ are U.S. pending trademarks of RegenLab USA and/or Regen Lab SA.
Now is the time to step into the future of medicine.
Get connected with us to Learn More.
Our Affiliated Locations: